|
"qin s"的相关文件
显示项目 1-25 / 73 (共3页)
1 2 3 > >>
每页显示[10|25|50]项目
| 國家衛生研究院 |
2024-08 |
Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): Updated overall survival from a randomised phase 3 study
|
Oh, DY;He, AR;Bouattour, M;Okusaka, T;Qin, S;Chen, LT;Kitano, M;Lee, CK;Kim, JW;Chen, MH;Suksombooncharoen, T;Ikeda, M;Lee, MA;Chen, JS;Potemski, P;Burris, HA, 3rd;Ostwal, V;Tanasanvimon, S;Morizane, C;Zaucha, RE;McNamara, MG;Avallone, A;Cundom, JE;Breder, V;Tan, B;Shimizu, S;Tougeron, D;Evesque, L;Petrova, M;Zhen, DB;Gillmore, R;Gupta, VG;Dayyani, F;Park, JO;Buchschacher, GL, Jr.;Rey, F;Kim, H;Wang, J;Morgan, C;Rokutanda, N;Żotkiewicz, M;Vogel, A;Valle, JW |
| 國家衛生研究院 |
2023-03-31 |
Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin ( plus GC) in patients (pts) with advanced biliary tract cancer (BTC) [Erratum:Annals of Oncology. 2022 Nov;33(Suppl. 9):S1462
|
Oh, D;He, AR;Qin, S;Chen, L;Okusaka, T;Vogel, A;Kim, JW;Suksombooncharoen, T;Lee, MA;Kitano, M;Burris, HA;Bouattour, M;Tanasa, S;Zaucha, RE;Avallone, A;Cundom, JE;Rokutanda, N;Żotkiewicz, M;Cohen, G;Valle, JW |
| 國立成功大學 |
2023 |
Effects of Boundary Conditions on Performance Prediction of Deep-Buried Ground Heat Exchangers for Geothermal Energy Utilization
|
Ma, Z.;Qin, S.;Zhang, Y.;Chen, W.-H.;Jia, G.;Cheng, Cheng C.;Jin, L. |
| 國立成功大學 |
2023 |
Plain language summary of the TOPAZ-1 study: durvalumab and chemotherapy for advanced biliary tract cancer
|
Oh, D.-Y.;He, A.R.;Qin, S.;Chen, L.-T.;Okusaka, T.;Vogel, A.;Kim, J.W.;Suksombooncharoen, T.;Lee, M.A.;Kitano, M.;Burris, H.;Bouattour, M.;Tanasanvimon, S.;McNamara, McNamara M.G.;Zaucha, R.;Avallone, Avallone A.;Tan, B.;Cundom, J.;Lee, C.-K.;Takahashi, H.;Ikeda, M.;Chen, J.-S.;Wang, J.;Makowsky, Makowsky M.;Rokutanda, N.;Żotkiewicz, M.;Kurland, J.F.;Cohen, G.;Valle, J.W. |
| 國家衛生研究院 |
2022-11 |
Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin ( plus GC) in patients (pts) with advanced biliary tract cancer (BTC)
|
Oh, DY;He, AR;Qin, S;Chen, LT;Okusaka, T;Vogel, A;Kim, JW;Lee, T;Lee, MA;Kitano, M;Burris, HA;Bouattour, M;Tanasanvimon, S;Zaucha, RE;Avallone, A;Cundom, JE;Rokutanda, N;Zotkiewicz, M;Cohen, G;Valle, JW |
| 臺大學術典藏 |
2022-09-20T06:48:39Z |
Prescription patterns of anti-diabetic medications and clinical outcomes in Asian patients with heart failure and diabetes mellitus
|
Chia Y.M.F.; Teng T.-H.K.; Tay W.T.; Anand I.; MacDonald M.R.; Yap J.; Chandramouli C.; Richards A.M.; Tromp J.; Ouwerkerk W.; Ling L.H.; Lam C.S.P.; Hung C.-L.; Liew H.B.; Narasimhan C.; Ngarmukos T.; Park S.W.; Reyes E.; Siswanto B.B.; Shimizu W.; Zhang S.; Fan X.; Chen K.; Wu L.; Xie Y.; Jin Q.; Ling T.; Li X.; Zhou F.; Zhou Y.; Xu D.; Zhang H.; Su Y.; Chen X.; Qin S.; Wang J.; Gong X.; Wu Z.; Yu C.M.; Sastry B.K.S.; Gopi A.; Raghu K.; Sridevi C.; Kaur D.; Naik A.; Parikh K.; Chandarana A.; Shah U.; Chag M.; Baxi H.; Gupta S.; Bhatia J.; Khakhkhar V.; Sankhla V.; Patel T.; Kapoor V.; Wander G.S.; Tandon R.; Chopra V.; Kumar M.; Sethi H.J.S.; Verma R.; Mittal S.; Sawhney J.; Sharma M.K.; Purayil M.P.; Tedjokusumo P.; Martanto E.; Erwinanto, Munawar M.; Pambudi J.A.; Lukito A.; Pardede I.; Thengker A.; Damay V.; Danny S.S.; Surarso R.; Noda T.; Nakajima I.; Wada M.; Ishibashi K.; Kurita T.; Yasuoka R.; Asai K.; Murai K.; Kubota Y.; Izumi Y.; Ikeda T.; Hisatake S.; Kabuki T.; Kiuchi S.; Hagiwara N.; Suzuki A.; Suzuki T.; Hong S.K.; Lee S.; Soo L.D.; Kim D.-H.; Shim J.; Park S.-M.; Roh S.-Y.; Kim Y.H.; Kim M.; Choi J.-I.; Na J.O.; Rha S.W.; Seo H.S.; Oh D.J.; Park C.G.; Kim E.J.; Joung B.; Uhm J.-S.; Lee M.H.; Cho I.-J.; Park H.-N.; Park H.-W.; Cho J.-G.; Yoon N.; Lee K.; Kim K.H.; Kim S.H.; Saharudin S.; Beh B.C.; Lee Y.W.; Yen C.H.; Othman M.K.; Augustine A.-A.; Asnawi M.H.M.; Mojolou R.A.; Tan Y.Z.; Arbain A.N.; Wong C.K.; Omar R.; Ghazi A.M.; Khelae S.K.; Chew D.S.P.; Yap L.B.; Hussin A.; Muhammad Z.; Azmee M.G.; Abidin I.Z.; Zhudi A.S.B.M.; Sari N.A.M.; Sridhar G.S.; Zuhdi A.S.M.; Ismail M.D.; Ong T.K.; Cham Y.L.; Khiew N.Z.; Said A.B.; Fong A.Y.Y.; Amin N.H.M.; Seng K.C.; Tan S.K.; Yew K.L.; Santos J.; Lim A.; Lapitan R.; Andal R.; Lopez E.; Sim K.L.D.; Tan B.Y.; Lim C.P.; Teo L.L.Y.; Chan L.L.H.; Chai P.; Wong C.C.R.; Poh K.K.; Yeo P.S.D.; Lee E.M.; Loh S.Y.; Ching M.E.; Khoo D.Z.L.; Yew M.S.; Huang W.; Leong K.T.G.; See J.H.J.; Lim Y.B.; Tan S.; Yeo C.; Chai S.C.; Jaufeerally F.R.; Tulsidas H.; Aung T.; Ong H.Y.; Ling L.F.; Soon D.K.N.; Yeh H.-I.; Kuo J.-Y.; Yen C.-H.; HWANG, JUEY-JEN; Chien K.-L.; Su T.-C.; Lin L.-Y.; Juang J.-M.; Lin Y.-H.; Chiang F.-T.; Lin J.-L.; Ho Y.-L.; Lee C.-M.; Lin P.-C.; Hung C.-S.; Chang S.-N.; Lin J.-W.; Hsu C.-N.; Yu W.-C.; Chao T.-F.; Sung S.-H.; Wang K.-L.; Leu H.-B.; Lin Y.-J.; Chang S.-L.; Huang P.-H.; Lo L.-W.; Wu C.-H.; Liang H.-Y.; Chang S.-S.; Hsiao L.-C.; Wang Y.-C.; Lu C.-R.; Wu H.-P.; Lin Y.-N.; Chen K.-W.; Lo P.-H.; Hsu C.-H.; Hsieh L.-C.; Chandavimol M.; Yingchoncharoen T.; Laothavorn P.; Tiyanon W.; Wongcharoen W.; Phrommintikul A.; on behalf of the ASIAN-HF Investigators |
| 臺大學術典藏 |
2022-09-06T02:41:54Z |
Prescription patterns of anti-diabetic medications and clinical outcomes in Asian patients with heart failure and diabetes mellitus
|
Chia Y.M.F.; Teng T.-H.K.; Tay W.T.; Anand I.; MacDonald M.R.; Yap J.; Chandramouli C.; Richards A.M.; Tromp J.; Ouwerkerk W.; Ling L.H.; Lam C.S.P.; Hung C.-L.; Liew H.B.; Narasimhan C.; Ngarmukos T.; Park S.W.; Reyes E.; Siswanto B.B.; Shimizu W.; Zhang S.; Fan X.; Chen K.; Wu L.; Xie Y.; Jin Q.; Ling T.; Li X.; Zhou F.; Zhou Y.; Xu D.; Zhang H.; Su Y.; Chen X.; Qin S.; Wang J.; Gong X.; Wu Z.; Yu C.M.; Sastry B.K.S.; Gopi A.; Raghu K.; Sridevi C.; Kaur D.; Naik A.; Parikh K.; Chandarana A.; Shah U.; Chag M.; Baxi H.; Gupta S.; Bhatia J.; Khakhkhar V.; Sankhla V.; Patel T.; Kapoor V.; Wander G.S.; Tandon R.; Chopra V.; Kumar M.; Sethi H.J.S.; Verma R.; Mittal S.; Sawhney J.; Sharma M.K.; Purayil M.P.; Tedjokusumo P.; Martanto E.; Erwinanto, Munawar M.; Pambudi J.A.; Lukito A.; Pardede I.; Thengker A.; Damay V.; Danny S.S.; Surarso R.; Noda T.; Nakajima I.; Wada M.; Ishibashi K.; Kurita T.; Yasuoka R.; Asai K.; Murai K.; Kubota Y.; Izumi Y.; Ikeda T.; Hisatake S.; Kabuki T.; Kiuchi S.; Hagiwara N.; Suzuki A.; Suzuki T.; Hong S.K.; Lee S.; Soo L.D.; Kim D.-H.; Shim J.; Park S.-M.; Roh S.-Y.; Kim Y.H.; Kim M.; Choi J.-I.; Na J.O.; Rha S.W.; Seo H.S.; Oh D.J.; Park C.G.; Kim E.J.; Joung B.; Uhm J.-S.; Lee M.H.; Cho I.-J.; Park H.-N.; Park H.-W.; Cho J.-G.; Yoon N.; Lee K.; Kim K.H.; Kim S.H.; Saharudin S.; Beh B.C.; Lee Y.W.; Yen C.H.; Othman M.K.; Augustine A.-A.; Asnawi M.H.M.; Mojolou R.A.; Tan Y.Z.; Arbain A.N.; Wong C.K.; Omar R.; Ghazi A.M.; Khelae S.K.; Chew D.S.P.; Yap L.B.; Hussin A.; Muhammad Z.; Azmee M.G.; Abidin I.Z.; Zhudi A.S.B.M.; Sari N.A.M.; Sridhar G.S.; Zuhdi A.S.M.; Ismail M.D.; Ong T.K.; Cham Y.L.; Khiew N.Z.; Said A.B.; Fong A.Y.Y.; Amin N.H.M.; Seng K.C.; Tan S.K.; Yew K.L.; Santos J.; Lim A.; Lapitan R.; Andal R.; Lopez E.; Sim K.L.D.; Tan B.Y.; Lim C.P.; Teo L.L.Y.; Chan L.L.H.; Chai P.; Wong C.C.R.; Poh K.K.; Yeo P.S.D.; Lee E.M.; Loh S.Y.; Ching M.E.; Khoo D.Z.L.; Yew M.S.; Huang W.; Leong K.T.G.; See J.H.J.; Lim Y.B.; Tan S.; Yeo C.; Chai S.C.; Jaufeerally F.R.; Tulsidas H.; Aung T.; Ong H.Y.; Ling L.F.; Soon D.K.N.; Yeh H.-I.; Kuo J.-Y.; Yen C.-H.; Hwang J.-J.; Chien K.-L.; Su T.-C.; LIAN-YU LIN; Juang J.-M.; Lin Y.-H.; Chiang F.-T.; Lin J.-L.; Ho Y.-L.; Lee C.-M.; Lin P.-C.; Hung C.-S.; Chang S.-N.; Lin J.-W.; Hsu C.-N.; Yu W.-C.; Chao T.-F.; Sung S.-H.; Wang K.-L.; Leu H.-B.; Lin Y.-J.; Chang S.-L.; Huang P.-H.; Lo L.-W.; Wu C.-H.; Liang H.-Y.; Chang S.-S.; Hsiao L.-C.; Wang Y.-C.; Lu C.-R.; Wu H.-P.; Lin Y.-N.; Chen K.-W.; Lo P.-H.; Hsu C.-H.; Hsieh L.-C.; Chandavimol M.; Yingchoncharoen T.; Laothavorn P.; Tiyanon W.; Wongcharoen W.; Phrommintikul A.; on behalf of the ASIAN-HF Investigators |
| 國家衛生研究院 |
2022-09 |
Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin ( plus GC) in patients (pts) with advanced biliary tract cancer (BTC)
|
Oh, DY;He, AR;Qin, S;Chen, LT;Okusaka, T;Vogel, A;Kim, JW;Suksombooncharoen, T;Lee, MA;Kitano, M;Burris, HA;Bouattour, M;Tanasanvimon, S;Zaucha, RE;Avallone, A;Cundom, JE;Rokutanda, N;Watras, M;Cohen, G;Valle, JW |
| 臺大學術典藏 |
2022-08-19T06:48:44Z |
Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study
|
Chung H.C.; Davis S.L.; Dev A.; Gane E.; George B.; He A.R.; Hochster H.; Hsu C.-H.; Ikeda M.; Lee J.; Lee M.; Mahipal A.; Manji G.; Morimoto M.; Numata K.; Pishvaian M.; Qin S.; Ryan D.; Ryoo B.-Y.; Sasahira N.; Stein S.; Strickler J.; Tebbutt N.; Chao Y.; Chen J.-S.; Bang Y.-J.; Bendell J.; Lee K.-H.; Wang Y.; Abdullah H.; Liu B.; Spahn J.; Hack S.P.; Verret W.; CHIH-HUNG HSU; Lee M.S. |
| 臺大學術典藏 |
2022-08-19T00:21:03Z |
Issues and controversies of hepatocellular carcinoma-targeted therapy clinical trials in Asia: Experts'opinion
|
Chen P.-J.; Furuse J.; Han K.-H.; CHIUN HSU; Lim H.-Y.; Moon H.; Qin S.; Ye S.-L.; Yeoh E.-M.; Yeo W. |
| 臺大學術典藏 |
2022-08-19T00:20:34Z |
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS�VESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO
|
Douillard J.-Y.; Yoshino T.; Yen Y.; Hsu C.-H.; Tabernero J.; Shen Y.-C.; CHIUN HSU; Chen S.-C.; Huang Y.-H.; Yen C.-J.; Qin S.; Bhattacharyya G.S.; Ikeda M.; Lim H.-Y.; Ho G.F.; Choo S.P.; Ren Z.; Malhotra H.; Ueno M.; Ryoo B.-Y.; Kiang T.C.; Tai D.; Vogel A.; Cervantes A.; Lu S.-N.; Pentheroudakis G.; Cheng A.-L.; Chen L.-T.; Martinelli E. |
| 臺大學術典藏 |
2022-08-19T00:20:33Z |
Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study
|
Tebbutt N.; Strickler J.; Stein S.; Ryan D.; Ryoo B.-Y.; Sasahira N.; Gane E.; George B.; He A.R.; Hochster H.; CHIUN HSU; Ikeda M.; Lee J.; Lee M.; Mahipal A.; Manji G.; Morimoto M.; Numata K.; Pishvaian M.; Qin S.; Dev A.; Davis S.L.; Chung H.C.; Chen J.-S.; Chao Y.; Bendell J.; Bang Y.-J.; Lee K.-H.; He A.R.; Wang Y.; Liu B.; Abdullah H.; Hack S.P.; Spahn J.; Lee M.S.; Ryoo B.-Y.; Hsu C.-H.; Numata K.; Stein S.; Verret W. |
| 國家衛生研究院 |
2022-07-04 |
Improving polygenic prediction in ancestrally diverse populations [Erratum:Nature Genetics. 2022 May 5;54(5):573-580.]
|
Ruan, Y;Lin, YF;Feng, YA;Chen, CY;Lam, M;Guo, Z;He, L;Sawa, A;Martin, AR;Qin, S;Huang, H;Ge, T |
| 臺大學術典藏 |
2022-06-10T06:10:59Z |
A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma
|
Qin S.; Chan S.L.; Sukeepaisarnjaroen W.; Han G.; Choo S.P.; Sriuranpong V.; Pan H.; Yau T.; Guo Y.; Chen M.; Ren Z.; Xu J.; Yen C.-J.; ZHONG-ZHE LIN; Manenti L.; Gu Y.; Sun Y.; Tiedt R.; Hao L.; Song W.; Tanwandee T. |
| 臺大學術典藏 |
2022-05-05T05:15:33Z |
Comparative genetic architectures of schizophrenia in East Asian and European populations
|
Lam M.; Chen C.-Y.; Li Z.; Martin A.R.; Bryois J.; Ma X.; Gaspar H.; Ikeda M.; Benyamin B.; Brown B.C.; Liu R.; Zhou W.; Guan L.; Kamatani Y.; Kim S.-W.; Kubo M.; Kusumawardhani A.A.A.A.; Liu C.-M.; Ma H.; Periyasamy S.; Takahashi A.; Xu Z.; Yu H.; Zhu F.; WEI J. CHEN; Faraone S.; Glatt S.J.; He L.; Hyman S.E.; Hwu H.-G.; McCarroll S.A.; Neale B.M.; Sklar P.; Wildenauer D.B.; Yu X.; Zhang D.; Mowry B.J.; Lee J.; Holmans P.; Xu S.; Sullivan P.F.; Ripke S.; O��Donovan M.C.; Daly M.J.; Qin S.; Sham P.; Iwata N.; Hong K.S.; Schwab S.G.; Yue W.; Tsuang M.; Liu J.; Ma X.; Kahn R.S.; Shi Y.; Huang H.; Schizophrenia Working Group of the Psychiatric Genomics Consortium, Indonesia Schizophrenia Consortium, Genetic REsearch on schizophreniA neTwork-China; the Netherlands (GREAT-CN); WEI J. CHEN |
| 國家衛生研究院 |
2022-05-05 |
Improving polygenic prediction in ancestrally diverse populations
|
Ruan, Y;Lin, YF;Feng, YA;Chen, CY;Lam, M;Guo, Z;He, L;Sawa, A;Martin, AR;Qin, S;Huang, H;Ge, T |
| 臺大學術典藏 |
2022-04-28T12:31:26Z |
Prescription patterns of anti-diabetic medications and clinical outcomes in Asian patients with heart failure and diabetes mellitus
|
Chia Y.M.F.; Teng T.-H.K.; Tay W.T.; Anand I.; MacDonald M.R.; Yap J.; Chandramouli C.; Richards A.M.; Tromp J.; Ouwerkerk W.; Ling L.H.; Lam C.S.P.; Hung C.-L.; Liew H.B.; Narasimhan C.; Ngarmukos T.; Park S.W.; Reyes E.; Siswanto B.B.; Shimizu W.; Zhang S.; Fan X.; Chen K.; Wu L.; Xie Y.; Jin Q.; Ling T.; Li X.; Zhou F.; Zhou Y.; Xu D.; Zhang H.; Su Y.; Chen X.; Qin S.; Wang J.; Gong X.; Wu Z.; Yu C.M.; Sastry B.K.S.; Gopi A.; Raghu K.; Sridevi C.; Kaur D.; Naik A.; Parikh K.; Chandarana A.; Shah U.; Chag M.; Baxi H.; Gupta S.; Bhatia J.; Khakhkhar V.; Sankhla V.; Patel T.; Kapoor V.; Wander G.S.; Tandon R.; Chopra V.; Kumar M.; Sethi H.J.S.; Verma R.; Mittal S.; Sawhney J.; Sharma M.K.; Purayil M.P.; Tedjokusumo P.; Martanto E.; Erwinanto, Munawar M.; Pambudi J.A.; Lukito A.; Pardede I.; Thengker A.; Damay V.; Danny S.S.; Surarso R.; Noda T.; Nakajima I.; Wada M.; Ishibashi K.; Kurita T.; Yasuoka R.; Asai K.; Murai K.; Kubota Y.; Izumi Y.; Ikeda T.; Hisatake S.; Kabuki T.; Kiuchi S.; Hagiwara N.; Suzuki A.; Suzuki T.; Hong S.K.; Lee S.; Soo L.D.; Kim D.-H.; Shim J.; Park S.-M.; Roh S.-Y.; Kim Y.H.; Kim M.; Choi J.-I.; Na J.O.; Rha S.W.; Seo H.S.; Oh D.J.; Park C.G.; Kim E.J.; Joung B.; Uhm J.-S.; Lee M.H.; Cho I.-J.; Park H.-N.; Park H.-W.; Cho J.-G.; Yoon N.; Lee K.; Kim K.H.; Kim S.H.; Saharudin S.; Beh B.C.; Lee Y.W.; Yen C.H.; Othman M.K.; Augustine A.-A.; Asnawi M.H.M.; Mojolou R.A.; Tan Y.Z.; Arbain A.N.; Wong C.K.; Omar R.; Ghazi A.M.; Khelae S.K.; Chew D.S.P.; Yap L.B.; Hussin A.; Muhammad Z.; Azmee M.G.; Abidin I.Z.; Zhudi A.S.B.M.; Sari N.A.M.; Sridhar G.S.; Zuhdi A.S.M.; Ismail M.D.; Ong T.K.; Cham Y.L.; Khiew N.Z.; Said A.B.; Fong A.Y.Y.; Amin N.H.M.; Seng K.C.; Tan S.K.; Yew K.L.; Santos J.; Lim A.; Lapitan R.; Andal R.; Lopez E.; Sim K.L.D.; Tan B.Y.; Lim C.P.; Teo L.L.Y.; Chan L.L.H.; Chai P.; Wong C.C.R.; Poh K.K.; Yeo P.S.D.; Lee E.M.; Loh S.Y.; Ching M.E.; Khoo D.Z.L.; Yew M.S.; Huang W.; Leong K.T.G.; See J.H.J.; Lim Y.B.; Tan S.; Yeo C.; Chai S.C.; Jaufeerally F.R.; Tulsidas H.; Aung T.; Ong H.Y.; Ling L.F.; Soon D.K.N.; Yeh H.-I.; Kuo J.-Y.; Yen C.-H.; Hwang J.-J.; Chien K.-L.; Su T.-C.; Lin L.-Y.; Juang J.-M.; Lin Y.-H.; Chiang F.-T.; Lin J.-L.; Ho Y.-L.; Lee C.-M.; Lin P.-C.; Hung C.-S.; Chang S.-N.; Lin J.-W.; Hsu C.-N.; Yu W.-C.; Chao T.-F.; Sung S.-H.; Wang K.-L.; Leu H.-B.; Lin Y.-J.; Chang S.-L.; Huang P.-H.; Lo L.-W.; Wu C.-H.; Liang H.-Y.; Chang S.-S.; Hsiao L.-C.; Wang Y.-C.; Lu C.-R.; Wu H.-P.; Lin Y.-N.; Chen K.-W.; Lo P.-H.; Hsu C.-H.; Hsieh L.-C.; Chandavimol M.; Yingchoncharoen T.; Laothavorn P.; Tiyanon W.; Wongcharoen W.; Phrommintikul A.; on behalf of the ASIAN-HF Investigators; KUO-LIONG CHIEN |
| 國家衛生研究院 |
2022-04-08 |
Mapping genomic loci implicates genes and synaptic biology in schizophrenia
|
Trubetskoy, V;Pardiñas, AF;Qi, T;Panagiotaropoulou, G;Awasthi, S;Bigdeli, TB;Bryois, J;Chen, CY;Dennison, CA;Hall, LS;Lam, M;Watanabe, K;Frei, O;Ge, T;Harwood, JC;Koopmans, F;Magnusson, S;Richards, AL;Sidorenko, J;Wu, Y;Zeng, J;Grove, J;Kim, M;Li, Z;Voloudakis, G;Zhang, W;Adams, M;Agartz, I;Atkinson, EG;Agerbo, E;Al Eissa, M;Albus, M;Alexander, M;Alizadeh, BZ;Alptekin, K;Als, TD;Amin, F;Arolt, V;Arrojo, M;Athanasiu, L;Azevedo, MH;Bacanu, SA;Bass, NJ;Begemann, M;Belliveau, RA;Bene, J;Benyamin, B;Bergen, SE;Blasi, G;Bobes, J;Bonassi, S;Braun, A;Bressan, RA;Bromet, EJ;Bruggeman, R;Buckley, PF;Buckner, RL;Bybjerg-Grauholm, J;Cahn, W;Cairns, MJ;Calkins, ME;Carr, VJ;Castle, D;Catts, SV;Chambert, KD;Chan, RCK;Chaumette, B;Cheng, W;Cheung, EFC;Chong, SA;Cohen, D;Consoli, A;Cordeiro, Q;Costas, J;Curtis, C;Davidson, M;Davis, KL;de Haan, L;Degenhardt, F;DeLisi, LE;Demontis, D;Dickerson, F;Dikeos, D;Dinan, T;Djurovic, S;Duan, J;Ducci, G;Dudbridge, F;Eriksson, JG;Fañanás, L;Faraone, SV;Fiorentino, A;Forstner, A;Frank, J;Freimer, NB;Fromer, M;Frustaci, A;Gadelha, A;Genovese, G;Gershon, ES;Giannitelli, M;Giegling, I;Giusti-Rodríguez, P;Godard, S;Goldstein, JI;González Peñas, J;González-Pinto, A;Gopal, S;Gratten, J;Green, MF;Greenwood, TA;Guillin, O;Gülöksüz, S;Gur, RE;Gur, RC;Gutiérrez, B;Hahn, E;Hakonarson, H;Haroutunian, V;Hartmann, AM;Harvey, C;Hayward, C;Henskens, FA;Herms, S;Hoffmann, P;Howrigan, DP;Ikeda, M;Iyegbe, C;Joa, I;Julià, A;Kähler, AK;Kam-Thong, T;Kamatani, Y;Karachanak-Yankova, S;Kebir, O;Keller, MC;Kelly, BJ;Khrunin, A;Kim, SW;Klovins, J;Kondratiev, N;Konte, B;Kraft, J;Kubo, M;Kučinskas, V;Kučinskiene, ZA;Kusumawardhani, A;Kuzelova-Ptackova, H;Landi, S;Lazzeroni, LC;Lee, PH;Legge, SE;Lehrer, DS;Lencer, R;Lerer, B;Li, M;Lieberman, J;Light, GA;Limborska, S;Liu, CM;Lönnqvist, J;Loughland, CM;Lubinski, J;Luykx, JJ;Lynham, A;Macek, M, Jr.;Mackinnon, A;Magnusson, PKE;Maher, BS;Maier, W;Malaspina, D;Mallet, J;Marder, SR;Marsal, S;Martin, AR;Martorell, L;Mattheisen, M;McCarley, RW;McDonald, C;McGrath, JJ;Medeiros, H;Meier, S;Melegh, B;Melle, I;Mesholam-Gately, RI;Metspalu, A;Michie, PT;Milani, L;Milanova, V;Mitjans, M;Molden, E;Molina, E;Molto, MD;Mondelli, V;Moreno, C;Morley, CP;Muntané, G;Murphy, KC;Myin-Germeys, I;Nenadić, I;Nestadt, G;Nikitina-Zake, L;Noto, C;Nuechterlein, KH;O'Brien, NL;O'Neill, FA;Oh, SY;Olincy, A;Ota, VK;Pantelis, C;Papadimitriou, GN;Parellada, M;Paunio, T;Pellegrino, R;Periyasamy, S;Perkins, DO;Pfuhlmann, B;Pietiläinen, O;Pimm, J;Porteous, D;Powell, J;Quattrone, D;Quested, D;Radant, AD;Rampino, A;Rapaport, MH;Rautanen, A;Reichenberg, A;Roe, C;Roffman, JL;Roth, J;Rothermundt, M;Rutten, BPF;Saker-Delye, S;Salomaa, V;Sanjuan, J;Santoro, ML;Savitz, A;Schall, U;Scott, RJ;Seidman, LJ;Sharp, SI;Shi, J;Siever, LJ;Sigurdsson, E;Sim, K;Skarabis, N;Slominsky, P;So, HC;Sobell, JL;Söderman, E;Stain, HJ;Steen, NE;Steixner-Kumar, AA;Stögmann, E;Stone, WS;Straub, RE;Streit, F;Strengman, E;Stroup, TS;Subramaniam, M;Sugar, CA;Suvisaari, J;Svrakic, DM;Swerdlow, NR;Szatkiewicz, JP;Ta, TMT;Takahashi, A;Terao, C;Thibaut, F;Toncheva, D;Tooney, PA;Torretta, S;Tosato, S;Tura, GB;Turetsky, BI;Üçok, A;Vaaler, A;van Amelsvoort, T;van Winkel, R;Veijola, J;Waddington, J;Walter, H;Waterreus, A;Webb, BT;Weiser, M;Williams, NM;Witt, SH;Wormley, BK;Wu, JQ;Xu, Z;Yolken, R;Zai, CC;Zhou, W;Zhu, F;Zimprich, F;Atbaşoğlu, EC;Ayub, M;Benner, C;Bertolino, A;Black, DW;Bray, NJ;Breen, G;Buccola, NG;Byerley, WF;Chen, WJ;Cloninger, CR;Crespo-Facorro, B;Donohoe, G;Freedman, R;Galletly, C;Gandal, MJ;Gennarelli, M;Hougaard, DM;Hwu, HG;Jablensky, AV;McCarroll, SA;Moran, JL;Mors, O;Mortensen, PB;Müller-Myhsok, B;Neil, AL;Nordentoft, M;Pato, MT;Petryshen, TL;Pirinen, M;Pulver, AE;Schulze, TG;Silverman, JM;Smoller, JW;Stahl, EA;Tsuang, DW;Vilella, E;Wang, SH;Xu, S;Adolfsson, R;Arango, C;Baune, BT;Belangero, SI;Børglum, AD;Braff, D;Bramon, E;Buxbaum, JD;Campion, D;Cervilla, JA;Cichon, S;Collier, DA;Corvin, A;Curtis, D;Forti, MD;Domenici, E;Ehrenreich, H;Escott-Price, V;Esko, T;Fanous, AH;Gareeva, A;Gawlik, M;Gejman, PV;Gill, M;Glatt, SJ;Golimbet, V;Hong, KS;Hultman, CM;Hyman, SE;Iwata, N;Jönsson, EG;Kahn, RS;Kennedy, JL;Khusnutdinova, E;Kirov, G;Knowles, JA;Krebs, MO;Laurent-Levinson, C;Lee, J;Lencz, T;Levinson, DF;Li, QS;Liu, J;Malhotra, AK;Malhotra, D;McIntosh, A;McQuillin, A;Menezes, PR;Morgan, VA;Morris, DW;Mowry, BJ;Murray, RM;Nimgaonkar, V;Nöthen, MM;Ophoff, RA;Paciga, SA;Palotie, A;Pato, CN;Qin, S;Rietschel, M;Riley, BP;Rivera, M;Rujescu, D;Saka, MC;Sanders, AR;Schwab, SG;Serretti, A;Sham, PC;Shi, Y;St Clair, D;Stefánsson, H;Stefansson, K;Tsuang, MT;van Os, J;Vawter, MP;Weinberger, DR;Werge, T;Wildenauer, DB;Yu, X;Yue, W;Holmans, PA;Pocklington, AJ;Roussos, P;Vassos, E;Verhage, M;Visscher, PM;Yang, J;Posthuma, D;Andreassen, OA;Kendler, KS;Owen, MJ;Wray, NR;Daly, MJ;Huang, H;Neale, BM;Sullivan, PF;Ripke, S;Walters, JTR;O'Donovan, MC |
| 臺大學術典藏 |
2022-02-21T02:04:35Z |
Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study
|
Qin S.; Ren Z.; Feng Y.-H.; Yau T.; Wang B.; Zhao H.; Bai Y.; Gu S.; Li L.; Hernandez S.; Xu D.-Z.; Mulla S.; Wang Y.; Shao H.; ANN-LII CHENG |
| 臺大學術典藏 |
2022-02-21T02:04:35Z |
Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT
|
Okusaka T.; Ikeda K.; Kudo M.; Finn R.; Qin S.; Han K.-H.; ANN-LII CHENG; Piscaglia F.; Kobayashi M.; Sung M.; Chen M.; Wyrwicz L.; Yoon J.-H.; Ren Z.; Mody K.; Dutcus C.; Tamai T.; Ren M.; Hayato S.; Kumada H. |
| 臺大學術典藏 |
2022-02-21T02:04:34Z |
Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial
|
Galle P.R.; Finn R.S.; Qin S.; Ikeda M.; Zhu A.X.; Kim T.-Y.; Kudo M.; Breder V.; Merle P.; Kaseb A.; Li D.; Mulla S.; Verret W.; Xu D.-Z.; Hernandez S.; Ding B.; Liu J.; Huang C.; Lim H.Y.; ANN-LII CHENG; Ducreux M. |
| 臺大學術典藏 |
2022-02-21T02:04:32Z |
Pharmacodynamic biomarkers predictive of survival benefit with lenvatinib in unresectable hepatocellular carcinoma: From the phase III REFLECT study
|
Finn R.S.; Kudo M.; ANN-LII CHENG; Wyrwicz L.; Ngan R.K.C.; Blanc J.-F.; Baron A.D.; Vogel A.; Ikeda M.; Piscaglia F.; Han K.-H.; Qin S.; Minoshima Y.; Kanekiyo M.; Ren M.; Dairiki R.; Tamai T.; Dutcus C.E.; Ikezawa H.; Funahashi Y.; Evans T.R.J. |
| 國家衛生研究院 |
2022-02-01 |
A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1
|
Oh, DY;He, AR;Qin, S;Chen, LT;Okusaka, T;Vogel, A;Kim, JW;Suksombooncharoen, T;Lee, MA;Kitano, M;Burris, HA;Bouattour, M;Tanasanvimon, S;Zaucha, R;Avallone, A;Cundom, J;Rokutanda, N;Xiong, J;Cohen, G;Valle, JW |
| 國立成功大學 |
2022 |
Ramucirumab as second-line treatment in Chinese patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib (REACH-2 China): A randomised, multicentre, double-blind study: RAM/PL + BSC for advanced HCC
|
Shao, G.;Bai, Y.;Yuan, X.;Chen, X.;Gu, S.;Gu, K.;Hu, C.;Liang, H.;Guo, Y.;Wang, J.;Yen, C.-J.;Lee, V.H.-F.;Wang, C.;Widau, R.C.;Zhang, W.;Liu, J.;Zhang, Q.;Qin, S. |
| 國立成功大學 |
2022 |
A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors
|
Chan, S.L.;Schuler, M.;Kang, Y.-K.;Yen, C.-J.;Edeline, J.;Choo, S.P.;Lin, C.-C.;Okusaka, T.;Weiss, K.-H.;Macarulla, T.;Cattan, S.;Blanc, J.-F.;Lee, K.-H.;Maur, Maur M.;Pant, S.;Kudo, M.;Assenat, E.;Zhu, A.X.;Yau, T.;Lim, H.Y.;Bruix, J.;Geier, A.;Guill�n-Ponce, C.;Fasolo, A.;Finn, R.S.;Fan, J.;Vogel, A.;Qin, S.;Riester, M.;Katsanou, V.;Chaudhari, M.;Kakizume, T.;Gu, Y.;Porta, D.G.;Myers, A.;Delord, J.-P. |
显示项目 1-25 / 73 (共3页)
1 2 3 > >>
每页显示[10|25|50]项目
|
